Publication stageIn Press Journal Pre-Proof
Disclosure statement. OH serves occasionally on advisory boards for Bayer AG and Gedeon Richter, and has designed and lectured at educational events of these companies. The other authors report no conflict of interest.
Funding. The study was supported by the Jane and Aatos Erkko Foundation (JH; grant number #170062), the Avohoidon tutkimussäätiö (JH; Foundation for Primary Care Research), the Yrjö Jahnsson Foundation (ET; grant number #20207328) and the Finnish Cultural Foundation (ET; grant number #00211101). None of the funders were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Paper presentation information. The findings reported in this paper were presented at the 69th Annual Scientific Meeting of the Society for Reproductive Investigation, Denver, CO; March, 15-19, 2022.
Condensation. The use of hormonal intrauterine devices was associated with several modest metabolic changes, suggestive of reduced cardiometabolic risk.
AJOG at a Glance.
A. Why was this study conducted?
The use of hormonal intrauterine devices is increasing globally, and many users opt for subsequent device(s). Thus, an increasing number of fertile aged individuals are exposed for several years to Levonorgestrel, calling for assessment of possibly related metabolic changes and large scale biomarker profiles.
B. What are the key findings?
After adjustment for covariates, levels of 141 metabolites differed between current users of a hormonal intrauterine devices and non-users of hormonal contraception. The metabolic patterns were similar irrespective of the duration of use; most of the metabolic alterations were not evident in previous users.
C. What does this study add to what is already known?
The use of hormonal intrauterine devices is associated with many multiple moderate metabolic changes, suggestive of reduced arterial cardiometabolic risk. The associations appeared mostly to be independent on the duration of use, and not to persist after discontinuation of use.
User LicenseCreative Commons Attribution (CC BY 4.0) |
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy